This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Jeffrey Ferguson
Senior Research Advisor Global Regulatory Affairs-CMC at Eli Lilly and Company


Jeff Ferguson is an experienced regulatory professional serving over 22 years in the Eli Lilly Global Regulatory Affairs - CMC organization with increasing levels of responsibility and influence.  His focus is in the development and registration of synthetically derived small molecules, including synthetic peptides and oligonucleotides.  He has successfully prepared and implemented CMC development and registration strategies for complex manufacturing processes, such as drug substance continuous manufacturing operations.  He currently serves as an Executive Director in Lilly’s GRA-CMC function with regulatory oversight and advisory responsibilities for approximately half of Lilly’s late stage small molecule portfolio, while also providing day-to-day support for multiple late stage CMC development programs.  He holds a BS in Chemistry and has 34 years of combined CMC regulatory experience in the pharmaceutical industry.

Agenda Sessions

  • Regulatory Perspectives on Development Approaches for Synthetic Peptides - Opportunities and Challenges